Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.327
Sell
RSI(14)
37.714
Neutral
STOCH(KDJ)(9,3,3)
21.844
Neutral
ATR(14)
1.575
High Vlolatility
CCI(14)
-165.352
Sell
Williams %R
70.315
Sell
TRIX(12,20)
-0.582
Sell
StochRSI(14)
52.701
Buy
Vericel Corp
VCEL30.570USD
-0.250-0.81%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
59.24MMarket Cap
93.16P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Vericel Corp
Currency: USD Updated: 2026-03-27Key Insights
Vericel Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 55.43.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vericel Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Vericel Corp Highlights
StrengthsRisks
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 39.87% year-on-year.
Fairly Valued
The company’s latest PE is 89.42, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 53.94M shares, decreasing 8.66% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 249.85K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
55.429
Target Price
+79.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Vericel Corp is 9.02, ranking 17 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 92.92M, representing a year-over-year increase of 23.27%, while its net profit experienced a year-over-year increase of 17.35%.
Score
Financials
9.32
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.98
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.81
Vericel Corp's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Vericel Corp is 5.14, ranking 150 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 89.42, which is 5234.70% below the recent high of 4770.06 and 975.33% above the recent low of -782.68.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 33/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Vericel Corp is 8.50, ranking 28 out of 157 in the Pharmaceuticals industry. The average price target is 55.00, with a high of 62.00 and a low of 50.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
55.429
Target Price
+88.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Vericel Corp
VCEL
8
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Vericel Corp is 6.34, ranking 120 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 33.98 and the support level at 26.83, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
31.046
Sell
MA10
31.663
Sell
MA20
32.551
Sell
MA50
35.065
Sell
MA100
36.577
Sell
MA200
36.443
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Vericel Corp is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 106.65%, representing a quarter-over-quarter decrease of 1.91%. The largest institutional shareholder is The Vanguard, holding a total of 3.57M shares, representing 7.01% of shares outstanding, with 1.41% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Conestoga Capital Advisors, LLC
William Blair Investment Management, LLC
Geneva Capital Management LLC
Congress Asset Management Company, LLP
GW&K Investment Management, LLC
BNP Paribas Asset Management USA, Inc.
Fidelity Management & Research Company LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Vericel Corp is 6.36, ranking 55 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Vericel Corp’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
1.23
VaR
+5.05%
240-Day Maximum Drawdown
+35.80%
240-Day Volatility
+50.89%
Return
Best Daily Return
60 days
+6.09%
120 days
+9.41%
5 years
+26.97%
Worst Daily Return
60 days
-5.33%
120 days
-5.33%
5 years
-23.43%
Sharpe Ratio
60 days
-2.12
120 days
-0.12
5 years
+0.00
Risk Assessment
Maximum Drawdown
240 days
+35.80%
3 years
+52.52%
5 years
+73.97%
Return-to-Drawdown Ratio
240 days
-0.81
3 years
-0.07
5 years
-0.14
Skewness
240 days
-0.22
3 years
+0.22
5 years
+0.46
Volatility
Realised Volatility
240 days
+50.89%
5 years
+54.13%
Standardised True Range
240 days
+5.84%
5 years
+6.30%
Downside Risk-Adjusted Return
120 days
-22.01%
240 days
-22.01%
Maximum Daily Upside Volatility
60 days
+32.64%
Maximum Daily Downside Volatility
60 days
+30.78%
Liquidity
Average Turnover Rate
60 days
+1.07%
120 days
+1.06%
5 years
--
Turnover Deviation
20 days
+18.34%
60 days
+19.78%
120 days
+18.68%
Peer Comparison
Pharmaceuticals
Vericel Corp
VCEL
7.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Innoviva Inc
INVA
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
